Research
Molecular
Orlistat's peak concentration stayed below 5 ng/mL, indicating minimal systemic absorption.
The low systemic absorption suggests a reduced risk of systemic side effects from orlistat.
StrongSupportsmedium confidence
Orlistat's peak concentration stayed below 5 ng/mL, and acarbose plasma levels were mostly undetectable, indicating minimal systemic absorption.
Why this rating
The study design involved blood sample collection for pharmacokinetic analysis.
Source
A Comparative Analysis of the Pharmacodynamic and Pharmacokinetic Properties of 2 Controlled‐Release Formulations Versus a Marketed Orlistat Product
Stefan Grudén et al. · Clinical Pharmacology in Drug Development · 2025
DOI 10.1002/cpdd.1503
other · n=20
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →